Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIN1 | Q13526 | 2/20 | 0.53 |
| ▸ | HTR1A | P08908 | 1/20 | 0.53 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.53 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.53 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.53 |
| ▸ | NPC1 | O15118 | 3/20 | 0.50 |
| ▸ | RAB9A | P51151 | 3/20 | 0.50 |
| ▸ | SGMS2 | Q8NHU3 | 1/20 | 0.50 |
| ▸ | RECQL | P46063 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 4/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.48 |
| ▸ | POLB | P06746 | 2/20 | 0.48 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.48 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.48 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.48 |
| ▸ | ATM | Q13315 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31234027 | 1.00 | PIN1 (0.53) | PIN1HTR1AADRA1DADRA1AADRA1B | |
| SCHEMBL2305236 | 0.85 | NPC1 (0.68) | PIN1HTR1AADRA1DADRA1AADRA1B | |
| SCHEMBL30015078 | 0.85 | NPC1 (0.68) | PIN1HTR1AADRA1DADRA1AADRA1B | |
| SCHEMBL9528862 | 0.83 | HTR1A (0.54) | PIN1HTR1AADRA1DADRA1AADRA1B | |
| SCHEMBL23884065 | 0.82 | SGMS2 (0.53) | PIN1HTR1AADRA1DADRA1AADRA1B | |
| SCHEMBL1137833 | 0.82 | HTR1A (0.53) | PIN1HTR1AADRA1DADRA1AADRA1B | |
| SCHEMBL7110475 | 0.82 | HTR1A (0.53) | PIN1HTR1AADRA1DADRA1AADRA1B | |
| SCHEMBL1937817 | 0.82 | HTR1A (0.53) | PIN1HTR1AADRA1DADRA1AADRA1B | |
| SCHEMBL23294854 | 0.82 | HTR1A (0.53) | PIN1HTR1AADRA1DADRA1AADRA1B | |
| SCHEMBL1141905 | 0.82 | TDP1 (0.65) | PIN1HTR1AADRA1DADRA1AADRA1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250388602-A1 | Tetrahydropyranopyrazole Derivatives for the Treatment of Cancer and Viral Infections | GENASE THERAPEUTICS B V (NL) | 2025-12-25 | — | — | US | disclosed |
| EP-4469461-B1 | TETRAHYDROPYRANOPYRAZOLE DERIVATIVES FOR THE TREATMENT OF CANCER AND VIRAL INFECTIONS | GENASE THERAPEUTICS B V (NL) | 2025-10-15 | — | — | EP | disclosed |
| EP-4469461-A1 | TETRAHYDROPYRANOPYRAZOLE DERIVATIVES FOR THE TREATMENT OF CANCER AND VIRAL INFECTIONS | Genase Therapeutics B.V. (NL) | 2024-12-04 | — | — | EP | disclosed |
| WO-2023144332-A1 | TETRAHYDROPYRANOPYRAZOLE DERIVATIVES FOR THE TREATMENT OF CANCER AND VIRAL INFECTIONS | GENASE THERAPEUTICS B.V. (NL) | 2023-08-03 | — | — | WO | disclosed |
| US-8501727-B2 | Short acting benzothiazepine calcium channel blockers and uses thereof | MILESTONE PHARMACEUTICALS INC. (CA) | 2013-08-06 | — | — | US | disclosed |
| US-20110144087-A1 | SHORT ACTING BENZOTHIAZEPINE CALCIUM CHANNEL BLOCKERS AND USES THEREOF | MILESTONE PHARMACEUTICALS INC. (CA) | 2011-06-16 | — | — | US | disclosed |
| EP-2330895-A1 | SHORT ACTING BENZOTHIAZEPINE CALCIUM CHANNEL BLOCKERS AND USES THEREOF | Milestone Pharmaceuticals Inc. (CA) | 2011-06-15 | — | — | EP | disclosed |
| WO-2010022259-A1 | SHORT ACTING BENZOTHIAZEPINE CALCIUM CHANNEL BLOCKERS AND USES THEREOF | MILESTONE PHARMACEUTICALS INC. (CA) | 2010-02-25 | — | — | WO | disclosed |
| US-5418241-A | Antiserotonin agents | SYNTHELABO (FR) | 1995-05-23 | — | — | US | disclosed |
| EP-0591026-A1 | Piperidine derivatives, their preparation and their use in therapy | SYNTHELABO (FR) | 1994-04-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110144087-A1 | SHORT ACTING BENZOTHIAZEPINE CALCIUM CHANNEL BLOCKERS AND USES THEREOF | RYR2, ORAI1, RYR1 | PIN1 1726/4885HTR1A 1571/4885ADRA1D 203/4885 |
| US-20250388602-A1 | Tetrahydropyranopyrazole Derivatives for the Treatment of Cancer and Viral Infections | CCNA1, KRAS, RSU1 | PIN1 2804/4885HTR1A 1713/4885ADRA1D 100/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.